Inclusion Criteria:  Lown PVC grade, II-IVA; in patients with coronary heart disease and comorbid PVC or non-organic heart disease, the PVC frequency was 3000-30000 times/24 h; New York Heart Association grade, I or II; ejection fraction, ≥45%; written informed consent to participate in the trial.  Exclusion Criteria:  presence of bradyarrhythmia (<50 beats/min), including sinus syndrome and atrioventricular block (second or third degree atrioventricular block); presence of persistent ventricular tachycardia, non-persistent ventricular tachycardia, and/or persistent atrial fibrillation; presence of severe PVC requiring treatment with other antiarrhythmic drugs; -presence of drug-induced, electrolyte-induced, or acid-base-induced arrhythmia; presence of uncontrolled or severe hypertension (e.g., grade ≥3 hypertension); presence of uncontrolled diabetes; presence of alanine aminotransferase or aspartate aminotransferase level ≥1.5-fold above the upper limit of normal, urea nitrogen level ≥1.2-fold above the upper limit of normal, and/or blood creatinine above the upper limit of normal; presence of severe respiratory dysfunction or asthma; presence of primary hematopoietic diseases, other systemic diseases (e.g., hyperthyroidism), poor peripheral circulation perfusion, severe peripheral vascular diseases, and/or PVC with unknown etiology; presence of allergic constitution, mental disorder, alcoholism, and/or smoking habit; pregnancy or lactation; ongoing β-blocker treatment or contraindications to β-blocker treatment; -participation in other clinical trials within the prior 3 months; and other reasons for lack of suitability to participate in this study, as determined by the investigators.